🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "huge turning point" in the battle against drug-resistant strains of the pathogen, according to researchers.

A Worldwide Health Concern

Cases of gonorrhoea are increasing around the world, with figures suggesting over 82 million new cases per year. Especially elevated rates are reported in Africa and nations within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. Across England, cases have reached a all-time high, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely development in the context of growing infection rates, escalating drug resistance and the highly restricted therapeutic options currently available.”

Medical experts are particularly alarmed about the surge in treatment-resistant strains. The World Health Organization has designated it as a "priority pathogen". Recent surveillance revealed that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Gain Clearance

One new antibiotic, also known as a brand name, was approved by the US FDA in recent days for use against gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Experts hope that specific application of this new drug will help hinder the emergence of superbugs.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, gained clearance in the same week. This treatment, which is additionally indicated for UTIs, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin stemmed from a innovative non-profit model for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to bring it to fruition.

“This milestone represents a significant shift in the therapy of superbug gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Clinical Trial Data and Global Access

According to results detailed in a major medical journal, zoliflodacin cured over nine in ten of genital gonorrhoea infections. This places it at an similar efficacy with the current standard treatment, which uses two antibiotics. The trial included over 900 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, the non-profit has the rights to make available and distribute the drug in numerous regions with limited resources.

Doctors directly involved have shared hope. Having a easy-to-administer therapy like this is seen as a "revolutionary step" for managing the epidemic. This is considered essential to reduce the burden of the infection for patients and to prevent the spread of untreatable gonorrhoea around the world.